research Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies
Extracellular vesicles show promise for treating diseases but face challenges in development and regulation.
Search
for
Sort by
Research
840-870 / 1000+ results 
research Development of finasteride/PHBV@polyvinyl alcohol/chitosan reservoir-type microspheres as a potential embolic agent: from in vitro evaluation to animal study
Created microspheres show potential for safe and effective use in prostate artery embolization.
research Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
The treatment showed significant hair regrowth in alopecia areata patients without side effects.
research 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
Persistent ED in Propecia users is not due to abnormal blood flow.
research Adverse events with finasteride or dutasteride: FAERS
Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
Rezpegaldesleukin shows promise for treating severe alopecia areata.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Effects of 5-alpha reductase inhibitors
5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
research Oral Presentations
The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
research 5‐alpha‐reductase inhibitor treatment for frontal fibrosing alopecia: an evidence‐based treatment update
5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
Laser-assisted drug delivery is generally safe with mostly mild side effects.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research A Natural Product Molecule of Artocarpus Heterophyllus Reverses Inflammation Due to the Effect of Acute Exposure of Prostate Tissue to Testosterone Enanthate in Wistar Rats
Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research Pharma maker recalls drug over undeclared anti-hypertensive drug
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
research A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid‐I in rat plasma
A reliable method was developed to measure aristolochic acid-I in rat blood.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research Recent European legal developments on second medical uses and dosage regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
research Cyberspace Chat: An Examination of Brand-Name vs Generic Finasteride: A look at Active Pharmaceutical Ingredient (API), Excipients, Bioequivalence, and Other Factors Affecting Efficacy
research Safety and efficacy of actinic keratoses reduction with a 3 day application of ingenol disoxate field treatment to the face, chest and balding scalp
The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
research Etoricoxib
A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Long-term reduction of C-reactive protein by LDL apheresis
LDL apheresis lowers inflammation and cardiovascular risk by reducing CRP levels long-term.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.